From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Reckitt Benckiser – still more than just a Covid-19 beneficiary...

By Chris Bailey | Tuesday 20 October 2020


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Back in July I loved up the health and hygiene giant Reckitt Benckiser (RB.) and noted ‘my target remains over £80 a share’. Well – let’s face it – it was not too difficult to be optimistic about a company during the time of a huge healthcare concern whose brands include Dettol, Vanish, Air Wick and Harpic…even before you consider FinishDurex, Gaviscon and Strepsils. You get the gist: Reckitt is a consumer staples giant well-attuned to today’s backdrop. And you can see this in today’s third quarter update…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 12:51:45